A Cross-Species Hydroquinone Model Replicates Smoking-Related Corneal Endothelial Oxidative Injury and Enables Therapeutic Screening of FGF10
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.3.12 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by Bryanna J Lee and 11 co-authors. Institution: Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, California, United States. Major MEDLINE topics: Hydroquinones, Oxidative Stress, Fibroblast Growth Factor 10, Endothelium, Corneal. 83 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NEI NIH HHS, NIH HHS.
Abstract (original language)
Purpose
To establish an in vitro model of smoking-associated oxidative injury to the corneal endothelium and evaluate an injury-mitigating factor.
Methods
Primary human and porcine corneal endothelial cells (CEnCs) were exposed to hydroquinone (HQ; 0-150 µM, 48 hours). Outcomes included viability (ATP-based assay), reactive oxygen species (ROS), and apoptosis (TUNEL). Bulk RNA sequencing (RNA-seq) profiled HQ (Nrf2 and Hippo-Yap pathways) and HQ ± fibroblast growth factor 10 (FGF10) responses under moderate stress (cadherin/Wnt programs). FGF10 dose-response (1-100 ng/mL) identified 30 ng/mL for subsequent HQ ± FGF10 studies. Western blotting provided protein validation.
Results
HQ caused dose-dependent loss of viability with increased ROS and apoptosis (EC50: 191.2 µM human; 151.2 µM porcine). RNA-seq showed induction of Nrf2 antioxidant/detoxification genes with attenuation of Hippo-Yap signaling. At 150 µM HQ, total Yap decreased and the pYap/Yap ratio increased, consistent with Yap inactivation. FGF10 improved viability across doses (1-100 ng/mL; plateau 30-100 ng/mL) and required cotreatment during HQ exposure. Using 30 ng/mL, FGF10 improved viability across HQ doses, reduced ROS at 100 to 150 µM, and decreased apoptosis at 50 to 100 µM. At 50 µM HQ, FGF10 increased cadherin/Wnt-related transcripts, while N-cadherin protein decreased and β-catenin remained stable, consistent with junctional remodeling rather than full endothelial-mesenchymal transition. Key injury and rescue phenotypes were consistent across species.
Conclusions
Our study supports HQ as a translatable in vitro model of smoking-related oxidative stress in CEnCs. FGF10 shows injury-mitigating and pro-regenerative effects, supporting further preclinical evaluation to preserve endothelial integrity and potentially lessen reliance on transplantation in corneal endothelial dystrophies.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, California, United States.
- Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California, United States.
Funding
- NEI NIH HHS
- NIH HHS
Cite
APA
Lee, B. J., Agarwal, D., Huang, J. H., Ivanova, A., Bu, J. J., Hill, C. A., Noguchi, T., Jun, J. H., Makarenkova, H. P., Wahlin, K. J., Shaw, P. X., & Afshari, N. A. (2026). A Cross-Species Hydroquinone Model Replicates Smoking-Related Corneal Endothelial Oxidative Injury and Enables Therapeutic Screening of FGF10. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.3.12
Vancouver
Lee BJ, Agarwal D, Huang JH, Ivanova A, Bu JJ, Hill CA, et al. A Cross-Species Hydroquinone Model Replicates Smoking-Related Corneal Endothelial Oxidative Injury and Enables Therapeutic Screening of FGF10. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.3.12
BibTeX
@article{Lee2026,
author = {Lee, Bryanna J and Agarwal, Devansh and Huang, John H and Ivanova, Anastasiia and Bu, Jennifer J and Hill, Christian A and Noguchi, Takako and Jun, Jong Hwa and Makarenkova, Helen P and Wahlin, Karl J and Shaw, Peter X and Afshari, Natalie A},
title = {A Cross-Species Hydroquinone Model Replicates Smoking-Related Corneal Endothelial Oxidative Injury and Enables Therapeutic Screening of FGF10},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.3.12}
}
EUVIMED